Manage your formulary budget
Proactively manage your pharmacy inventory
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||A tablet suitable for use in the treatment of microbial infections, which tablet comprises from 80 to 98% (w/w) of a combination of a 2,4-diaminopyrimidine with a sulphonamide and not more than 20% (w/w) of both a granulating and a disintegrating agent, the combination having a particle size less than 40 .mu.m and the disintegrating agent having a swelling capacity greater than 5 ml/g.|
|Inventor(s):||Torode; Allan J. (Basildon, GB2), Harden; David (Sidcup, GB2), Spence; John (Bickley, GB2)|
|Assignee:||Burroughs Wellcome Co. (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||6758/74||Feb 14, 1974|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||A108475||<disabled in preview>|
|Austria||344915||<disabled in preview>|
|Australia||468465||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.